430 related articles for article (PubMed ID: 23897954)
21. Breast cancer recurrence according to molecular subtype.
Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
[TBL] [Abstract][Full Text] [Related]
22. Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation.
Wilkinson JB; Shah C; Amin M; Nadeau L; Shaitelman SF; Chen PY; Grills IS; Martinez AA; Mitchell CK; Wallace MF; Vicini FA
Clin Breast Cancer; 2017 Feb; 17(1):55-60. PubMed ID: 27666436
[TBL] [Abstract][Full Text] [Related]
23. Breast cancer subtypes and the risk of local and regional relapse.
Voduc KD; Cheang MC; Tyldesley S; Gelmon K; Nielsen TO; Kennecke H
J Clin Oncol; 2010 Apr; 28(10):1684-91. PubMed ID: 20194857
[TBL] [Abstract][Full Text] [Related]
24. Histological grade as an alternative to the Ki67 labeling index is only available for luminal-type breast cancers.
Hayashi S; Kitada M; Sato K; Matsuda Y; Ishibashi K; Oikawa K; Miyokawa N; Hirata S
Breast Cancer; 2014 Jan; 21(1):47-51. PubMed ID: 22467403
[TBL] [Abstract][Full Text] [Related]
25. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
[TBL] [Abstract][Full Text] [Related]
26. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
27. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
[TBL] [Abstract][Full Text] [Related]
28. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
29. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
30. Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer.
Park HS; Kim S; Kim K; Yoo H; Chae BJ; Bae JS; Song BJ; Jung SS
World J Surg Oncol; 2012 Jan; 10():4. PubMed ID: 22226178
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
32. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of molecular subtypes, ki67 expression and impact of postmastectomy radiation therapy in breast cancer patients with negative lymph nodes after mastectomy.
Selz J; Stevens D; Jouanneau L; Labib A; Le Scodan R
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1123-32. PubMed ID: 22572073
[TBL] [Abstract][Full Text] [Related]
34. The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival.
Vasconcelos I; Hussainzada A; Berger S; Fietze E; Linke J; Siedentopf F; Schoenegg W
Breast; 2016 Oct; 29():181-5. PubMed ID: 27544822
[TBL] [Abstract][Full Text] [Related]
35. Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
Dalenc F; Penault-Llorca F; Cohen M; Houvenaeghel G; Piat JM; Liegeois P; Puyuelo L; Suchaud JP; Zouai M; Lacroix-Triki M; Radosevic-Robin N; Benkanoun C; Attar-Rabia H; Chauvet MP; Gligorov J; Belkacemi Y
Clin Breast Cancer; 2017 Apr; 17(2):107-116. PubMed ID: 27856201
[TBL] [Abstract][Full Text] [Related]
36. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
37. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
[TBL] [Abstract][Full Text] [Related]
38. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.
Yue Y; Liang J; Wu Y; Tong W; Li D; Cao X; Wang X
Technol Cancer Res Treat; 2022; 21():15330338221132669. PubMed ID: 36254567
[No Abstract] [Full Text] [Related]
39. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.
Livi L; Meattini I; Saieva C; Franzese C; Di Cataldo V; Greto D; Franceschini D; Scotti V; Bonomo P; Nori J; Sanchez L; Vezzosi V; Bianchi S; Cataliotti L; Biti G
Cancer; 2012 Jul; 118(13):3236-43. PubMed ID: 22028054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]